| 000 | 01898 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250518014648.0 | ||
| 264 | 0 | _c20210902 | |
| 008 | 202109s 0 0 eng d | ||
| 022 | _a2173-5743 | ||
| 024 | 7 |
_a10.1016/j.reuma.2018.08.009 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _ade Abreu, Paloma | |
| 245 | 0 | 0 |
_aSafety and Survival Associated with Biologic Therapies: First Report of the Biobadaguay on the Paraguayan-Uruguayan Registry of Adverse Events with Biologic Therapies. _h[electronic resource] |
| 260 |
_bReumatologia clinica _c |
||
| 300 |
_a396-404 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Observational Study | ||
| 650 | 0 | 4 |
_aAdalimumab _xadverse effects |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadverse effects |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadverse effects |
| 650 | 0 | 4 |
_aArthritis, Juvenile _xdrug therapy |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdrug therapy |
| 650 | 0 | 4 |
_aBiological Products _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aParaguay |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRegistries |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aUruguay |
| 700 | 1 | _aÁvila-Pedretti, Gabriela | |
| 700 | 1 | _aMorel, Zoilo | |
| 700 | 1 | _aAcosta, María Isabel | |
| 700 | 1 | _aCabrera-Villalba, Sonia | |
| 700 | 1 | _aMelgarejo, Patricia | |
| 700 | 1 | _aFranco, Marco | |
| 700 | 1 | _aDelgadillo, Pedro | |
| 700 | 1 | _aRomán, Lourdes | |
| 700 | 1 | _aElizaur, Juan Gabriel | |
| 700 | 1 | _aParedes, Ernesto | |
| 700 | 1 | _aCordovilla, Darwin Octavio | |
| 700 | 1 | _aPalleiro, Daniel | |
| 700 | 1 | _aAlbanese, Miguel | |
| 700 | 1 | _aMazzoleni, Julio | |
| 773 | 0 |
_tReumatologia clinica _gvol. 16 _gno. 5 Pt 2 _gp. 396-404 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.reuma.2018.08.009 _zAvailable from publisher's website |
| 999 |
_c29207553 _d29207553 |
||